Financial Performance - The company's operating revenue for Q1 2024 was ¥76,861,627.55, representing a year-on-year increase of 4.85%[5] - The net profit attributable to shareholders was a loss of ¥16,041,506.14, with a basic earnings per share of -¥0.02[5][6] - The company reported a net loss of RMB -191,962,972.41 for Q1 2024, compared to a net loss of RMB -175,921,466.27 in Q1 2023[18] - The net profit for Q1 2024 was -16,041,506.14 RMB, compared to -22,991,377.51 RMB in Q1 2023, showing an improvement of approximately 30% year-over-year[22] - Operating profit for Q1 2024 was -17,208,207.06 RMB, an improvement from -20,999,994.59 RMB in the same period last year[22] - The total comprehensive income for Q1 2024 was -16,041,506.14 RMB, compared to -22,991,377.51 RMB in Q1 2023, indicating a positive trend in overall financial performance[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,483,165,176.81, down 8.70% from the previous year[6] - As of March 31, 2024, total assets amounted to RMB 1,483,165,176.81, down from RMB 1,624,560,125.88 at the end of 2023[18] - Total liabilities decreased to RMB 569,816,757.99 from RMB 693,517,978.39 at the end of 2023, reflecting a reduction of approximately 17.8%[18] - The total equity attributable to shareholders was RMB 913,348,418.82, down from RMB 931,042,147.49 at the end of 2023[18] Cash Flow - The net cash flow from operating activities was -¥20,674,871.45[5] - The cash flow from operating activities in Q1 2024 was -20,674,871.45 RMB, compared to -16,867,851.74 RMB in Q1 2023, indicating a worsening cash flow situation[27] - Cash flow from investment activities in Q1 2024 was 81,217,845.65 RMB, a significant recovery from -108,914,490.26 RMB in Q1 2023[27] - The company reported a cash and cash equivalents balance of 282,930,347.78 RMB at the end of Q1 2024, down from 475,261,821.28 RMB at the end of Q1 2023[27] Shareholder Information - The company has a total of 20,779 common shareholders at the end of the reporting period[12] - The largest shareholder, Lingkang Holdings Group Co., Ltd., holds 339,652,800 shares, accounting for 47.09% of total shares[13] Operating Costs and Revenue - Total operating revenue for Q1 2024 was RMB 76,861,627.55, an increase of 7.4% compared to RMB 73,303,587.38 in Q1 2023[21] - Total operating costs for Q1 2024 were RMB 94,759,740.05, slightly decreased from RMB 94,993,229.26 in Q1 2023[21] - Operating costs included RMB 33,008,973.81 in cost of goods sold, up from RMB 27,550,894.23 in the previous year, indicating a 19.7% increase[21] - Total revenue from sales and services received in Q1 2024 was 71,723,378.82 RMB, up from 65,651,043.72 RMB in Q1 2023, representing an increase of about 9%[25] Research and Development - Research and development expenses increased to 4,772,080.07 RMB in Q1 2024 from 3,470,253.82 RMB in Q1 2023, reflecting a growth of approximately 37%[22] Financial Management - The company incurred financial expenses of -332,164.72 RMB in Q1 2024, a decrease from 107,918.44 RMB in Q1 2023, indicating improved financial management[22] - The weighted average return on net assets was -1.74%[6] - The company is focusing on improving its financial performance and reducing losses in the upcoming quarters[10]

Financial Performance - The net profit attributable to the parent company's shareholders for 2023 is negative, leading the board to propose no profit distribution or capital reserve transfer for the year[6]. - The company's operating revenue for 2023 was ¥196.83 million, a decrease of 31.95% compared to ¥289.26 million in 2022[22]. - The net profit attributable to shareholders was -¥151.50 million, an improvement of 22.65% from -¥195.86 million in the previous year[22]. - The basic earnings per share for 2023 was -¥0.21, showing a 22.22% improvement from -¥0.27 in 2022[23]. - The total assets decreased by 12.45% to ¥1,624.56 million at the end of 2023, down from ¥1,855.48 million at the end of 2022[22]. - The company's net assets attributable to shareholders decreased by 17.94% to ¥931.04 million from ¥1,134.64 million in 2022[22]. - The net cash flow from operating activities improved by 42.92%, reaching -¥37.87 million compared to -¥66.36 million in 2022[22]. - The weighted average return on equity was -14.42%, a slight improvement from -14.89% in the previous year[23]. - The company reported a total of ¥40.09 million in government subsidies related to normal business operations in 2023[27]. Audit and Compliance - The company has received a standard unqualified audit report from Zhongshun Zhonghuan Accounting Firm[5]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting investment risks[7]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not disclosed any significant changes in its governance structure or major financial indicators in the report[10]. - The company adheres to strict information disclosure obligations, ensuring timely, accurate, and complete communication with investors[132]. - The company received a warning and a fine from the China Securities Regulatory Commission on April 19, 2023, due to regulatory issues[146]. Market and Industry Trends - In 2023, the pharmaceutical industry faced a 3.7% decline in revenue, totaling RMB 25,205.7 billion, and a 15.1% decrease in total profit, amounting to RMB 3,473 billion[36]. - The pharmaceutical industry is undergoing a transformation period, with policies promoting innovation and high-quality development[36]. - The average price reduction for successfully negotiated drugs in the latest medical insurance directory adjustment was 61.7%[38]. - The aging population in China is driving demand for healthcare services, which is expected to boost the pharmaceutical market[18]. - The Chinese pharmaceutical industry is facing pressures from rising raw material costs and stricter regulations, which may lead to increased competition among companies[16]. Research and Development - The company is committed to increasing R&D investment, achieving registration for two new injectable products in 2023[1]. - The company is actively expanding high-margin new product areas and has made significant progress in research and development, focusing on major disease categories such as oncology and cardiovascular drugs[43][45]. - The company has established a nationwide marketing network covering over 6,500 secondary hospitals, utilizing a distributor sales model to enhance market penetration[46]. - The company is focusing on optimizing resource allocation and enhancing market access for newly approved products to boost sales volume[32]. - The company is enhancing internal governance and operational standards in compliance with relevant laws and regulations[33]. - The company has a robust independent production, procurement, and sales system, not reliant on the controlling shareholder or related parties[134]. - The company has established a mature R&D system, but new product development carries inherent risks, including long cycles, high investment, and high failure rates[124]. Governance and Management - The company maintains independence from its controlling shareholder in terms of personnel, assets, and financial operations, ensuring a clear separation of interests[133]. - The company has a diverse management team with extensive experience in various sectors, enhancing its operational capabilities[139]. - The management team has over 15 years of experience in the pharmaceutical industry, ensuring high decision-making efficiency and execution capability[47]. - The company has a structured remuneration decision process for its senior management, based on performance evaluations[144]. - The company has established effective performance evaluation and incentive mechanisms to enhance management efficiency and align with its growth objectives[131]. Environmental and Social Responsibility - The company has invested a total of 12.04 million yuan in poverty alleviation and rural revitalization projects, with all funds allocated to direct support initiatives[176]. - The company continues to focus on social responsibility and economic development, actively engaging in initiatives that support community welfare and environmental protection[177]. - The company has developed an emergency response plan for environmental incidents, which was filed with the Haikou Environmental Protection Bureau on May 2, 2017[173]. - The company has not reported any administrative penalties due to environmental issues during the reporting period[175]. - The company has obtained a pollution discharge permit on April 8, 2021, from the Hainan Provincial Ecological Environment Protection Department[174]. Future Outlook and Strategy - The company aims to enhance its product pipeline and invest in R&D, focusing on oncology, liver disease, and cardiovascular drugs, among others[20]. - The company plans to actively participate in national drug procurement and expand its market presence for newly approved products[22]. - The company intends to accelerate industry consolidation through investments and acquisitions to expand its healthcare service offerings[23]. - The company plans to implement measures to protect minority investors' rights during the issuance of convertible bonds, including commitments to not interfere with management activities[182]. - The company is committed to prioritizing cash dividends in profit distribution when conditions allow[180].

灵康药业集团股份有限公司 关于募集资金年度存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码:603669 证券简称:灵康药业 公告编号:2024-016 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 1、 2015 年首次公开发行股票 经中国证券监督管理委员会证监许可〔2015〕828 号文核准，并经贵所同意，本公司由 主承销商中信证券股份有限公司向社会公众公开发行人民币普通股（A 股）股票 6,500 万股， 发行价为每股人民币 11.70 元，共计募集资金 76,050.00 万元，坐扣承销和保荐费用 4,263.00 万元(承销及保荐费总计 4,563.00 万元，已预付 300.00 万元)后的募集资金为 71,787.00 万元， 已由主承销商中信证券股份有限公司于 2015 年 5 月 25 日汇入本公司募集资金监管账户，减 除已预付的承销费和保荐费用 300.00 万元后的募集资金为 71,487.00 万元。另减除上网发行 费、招股说明书印刷费、申报会计师 ...

灵康药业集团股份有限公司 董事会审计委员会工作细则 第二章 审计委员会的人员组成 第四条 审计委员会成员由董事会从董事会成员中任命，并由 3 名或以上成员组 成。 灵康药业集团股份有限公司 董事会审计委员会工作细则 （2024 年 4 月修订） 第一章 总 则 第一条 为了提高公司治理水平，强化董事会决策功能，完善公司治理结构，规 范公司董事会审计委员会的运作，根据《公司法》、《证券法》、《上市公司治理准则》、 《企业内部控制基本规范》、《上海证券交易所股票上市规则》、《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等法律法规以及《公司章程》的规定，制定 本实施细则。 第二条 审计委员会是董事会下设的专门委员会，对董事会负责，向董事会报告 工作。 第三条 审计委员会成员须保证足够的时间和精力履行委员会的工作职责，勤勉 尽责，切实有效地监督公司的外部审计,指导公司内部审计工作，促进公司建立有效 的内部控制并提供真实、准确、完整的财务报告。 第五条 审计委员会成员原则上须独立于公司的日常经营管理事务。审计委员会 中独立董事委员应当过半数。 第六条 审计委员会全部成员应当为不在上市公司担任高级管理人员 ...

证券代码：603669 证券简称：灵康药业 公告编号：2024-014 灵康药业集团股份有限公司 2023年度拟不进行利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司 2023 年度拟不进行利润分配，不进行资本公积金转增股本。 本次利润分配方案已经公司第四届董事会第十一次会议、第四届监事会 第十一次会议审议通过，尚需提交公司 2023 年年度股东大会审议。 一、利润分配及资本公积转增股本方案内容 经中审众环会计师事务所（特殊普通合伙）审计，公司 2023 年度母公司的 净利润-172,562,673.75 元，加上年初未分配利润 12,854,251.27 元，提取法定 盈余公积后，公司 2023 年末累计可供股东分配的利润为-159,708,422.48 元。 2024 年 4 月 18 日，公司召开的第四届董事会第十一次会议和第四届监事会 第十一次会议审议通过《公司 2023 年度利润分配预案》，拟定 2023 年度利润分 配预案为：不进行现金股利分配，也不进行资本公积转增股本 ...

证券代码:603669 证券简称:灵康药业 公告编号:2024-017 委托理财期限：单个理财产品的投资期限不超过 12 个月 履行的审议程序：公司于 2024 年 4 月 18 日召开了第四届董事会第十一 次会议，审议通过了《关于使用部分闲置自有资金进行现金管理的议案》 一、委托理财概况 （一）委托理财目的：为提高闲置自有资金使用效率，降低财务成本，进一 步提高公司整体收益，在不影响公司正常生产经营资金需求和有效控制风险的前 提下，公司拟对部分闲置自有资金进行现金管理，用于投资安全性高、流动性好 的理财产品。 （二）资金来源：闲置自有资金。 灵康药业集团股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 委托理财受托方：银行、券商、信托公司、资产管理公司以及基金管理 公司等金融机构 委托理财额度：单日最高余额不超过 1 亿元，在确保不影响公司日常运 营的情况下滚动使用 委托理财产品名称：委托理财产品 （三）委托理财产品类型：银行、券商、信托公司、资产 ...

关于补选董事、监事及聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、补选董事的情况 灵康药业集团股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召开 第四届董事会第十一次会议，审议通过了《关于补选董事的议案》。经公司董事 会提名，董事会提名委员会对董事候选人的任职资格审核，同意提名刘力明先生 为公司第四节董事会非独立董事候选人（候选人简历附后），任期自公司股东大 会审议通过之日起至第四届董事会任期届满之日止。本次补选董事事项尚需提交 2023 年年度股东大会审议。 二、补选监事的情况 证券代码:603669 证券简称:灵康药业 公告编号:2024-022 灵康药业集团股份有限公司 公司于 2024 年 4 月 18 日召开第四届监事会第十一次会议，审议通过了《关 于补选监事的议案》。同意提名方现军先生（简历附后）为公司第四届监事会监 事候选人，任期自公司股东大会审议通过之日起至第四届监事会任期届满之日止。 本次补选监事事项尚需提交 2023 年年度股东大会审议。 三、聘任高级 ...

关于使用部分暂时闲置募集资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召开 第四届董事会第十一次会议及第四届监事会第十一次会议，审议通过了《关于使 用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司在不影响募 投项目资金使用进度安排及保证募集资金安全的前提下，使用总额不超过人民币 3 亿元的暂时闲置募集资金，向各金融机构购买安全性高、流动性好，产品期限 不超过 12 个月有保本约定的理财产品或存款类产品，使用期限自公司第四届董 事会第十一次会议审议通过之日起 12 个月。在上述使用期限及额度范围内，资 金可循环滚动使用，期满后归还至公司募集资金专管账户。董事会授权董事长行 使该项投资决策权并签署相关法律文件，具体由公司财务部负责组织实施。相关 事宜公告如下： 证券代码：603669 证券简称：灵康药业 公告编号：2024-018 灵康药业集团股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会《关于 ...

关于灵康药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：灵康药业集团股份有限公司 审计单位：中审众环会计师事务所（特殊普通合伙） 联系电话：027-85424329 HI: Tp - 837-06701215 关于灵康药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 时 = 项目 次 六 = 众坏专字(2024) 0300058 号 灵康药业集团股份有限公司全体股东: 我们接受委托,在审计了灵康药业集团股份有限公司(以下简称"灵康药业公司")2023 年 12月31日合并及母公司的资产负债表,2023年度合并及母公司的利润表、合并及母公 司的现金流量表和合并及母公司的股东权益变动表以及财务报表附注的基础上,对后附的 《上市公司 2023年度非经营性资金占用及其他关联资金往来的情况汇总表》(以下简称"汇 总表")进行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8号 -- 上市公司资金往来、对外担保的监管要求》的规定,编制和披露汇总表、提供真实、合 法、完整的审核证据是灵康药业公司管理层的 ...

立性的相关要求。 灵康药业集团股份有限公司董事会 灵康药业集团股份有限公司董事会 关于 2023 年度独立董事独立性自查情况的专项报告 根据证监会《上市公司独立董事管理办法》、上海证券交易所《股票上市规 则》、《上市公司自律监管指引第 1 号--规范运作》等要求，灵康药业集团股份 有限公司董事会就公司在任独立董事何超先生、潘自强先生、何前女士的独立 性情况进行评估并出具如下专项意见： 经核查，独立董事何超先生、潘自强先生、何前女士的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在 公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，符合《上市公司独立董事管理办法》、 《上海证券交易所上市公司自律监管指引第 1 号--规范运作》中对独立董事独 2024 年 4 月 18 日 ...